Abstract. The MAPK signaling pathway plays a crucial role in tumorgenesis and cell proliferation in human papillary thyroid carcinoma (PTC). Ret/PTC rearrangements, RAS and BRAF mutations, the main non-overlapping genetic alterations all leading to MAPK cascade activation, are cumulatively identified in 60-80% of PTCs. In approximately one-fourth of the cases, oncogenic background potentially contributing to MAPK activation in PTC might be different. We therefore attempted to evaluate the mutational status of genes encoding other members of RAF family known to act upstream of MAPKs, ARAF and CRAF (RAF-1). In addition we also analyzed the MET gene that encodes hepatocyte growth factor/scatter factor receptor overexpressed in most of PTCs and a MAPK cascade contributor. In 129 Japanese patients with PTC, BRAF T1799A was detected in 65 cases (50.4%), and the remaining 64 tumor specimens were subjected to mutation analysis of kinase domains of ARAF, CRAF and MET genes, and hotspots of K-and N-RAS genes. No ARAF, CRAF, MET, K-and N-RAS mutations were revealed. Based on these observations, we concluded that despite the fact that ARAF, CRAF and MET are actively expressed, alterations of these genes are rare in PTC and unlikely to play a perceptible role in the molecular pathogenesis of this type of human malignancy.
THE discovery of BRAF T1799A mutation in papillary thyroid cancer (PTC) has been the most striking advancement in thyroid cancer research field during the last several years. Since the first report on BRAF T1799A mutation in thyroid cancer [1] , numerous studies have rapidly been done within a short time.
BRAF T1799A transversion is found in approximately 45% of PTCs (range, 29%-69%), being the most common oncogene thus far identified in thyroid papillary carcinoma [1] [2] [3] [4] [5] . Besides BRAF T1799A , activating RAS mutations and RET/PTC rearrangements are observed in 20-30% and 10-30% sporadic PTC, respectively [6] [7] [8] [9] , leading to a common outcome, MAPK signaling pathway activation considered to be a paradigm in PTC. Importantly, BRAF T1799A , RET/PTC rearrangements and RAS mutations are mutually exclusive and never coexist in one tumor [10] [11] [12] . Thus a single oncogenic alteration along the linear MAPK cascade is likely to suffice thyrocyte transformation and tumorigenic drive in PTC.
Giordano et al. recently demonstrated that BRAF T1799A , RET/PTC or RAS mutations could be identified in 31 (73.8%) of 42 PTCs [13] leaving a room for approximately one-fourth of the cases to not be presented with the most common known gene mutation. In MAPK cascade, RAF family proteins include three isoforms, ARAF, BRAF and CRAF (also known as RAF-1). All these proteins have a conserved amino-terminal regulatory region and a carboxy-terminal protein kinase domain whose mutational status in PTC is unknown. In this study, we analyzed genomic DNA to detect somatic mutations in ARAF and CRAF genes in BRAF T1799A mutation-negative PTCs in order to address the possible implications of alterations of these genes. In addition, in BRAF T1799A negative tumors we also assessed the status of MET gene whose product overexpression has been reported in approximately 70% of PTCs [14] . MET is one of the target genes in the Wnt pathway whose impairment has been reported in a large subset of PTC [15] [16] [17] . Similarly to other receptor tyrosine kinases, MET protein can activate MAPK signaling contributing in this way to cell proliferation. We therefore considered this gene as one of the possible candidates for mutational analysis in PTC.
Materials and Methods

Tissue collection
Thyroid tumor tissues were selected from 129 PTCs paraffin blocks filed at the Department of Pathology, Nagasaki University School of Medicine, Japan. All thyroid tumors were independently diagnosed by two experienced pathologists based on the histopathological typing of the World Health Organization [18] as papillary carcinoma.
Protocols for the present study were approved by the Committee for Ethical Issues on Human Genome and Gene Analysis of Nagasaki University.
DNA extraction
DNA from paraffin-embedded thyroid tumor specimens was extracted from five 10 µm-thick sections after manual microdissection, resulting in selection of >90% tumor cells. Genomic DNA was isolated using DEXPAT reagent (TaKaRa Co., Otsu, Japan) and PCR amplified using specific primers (Table 1) .
In order to create a XbaI restriction site in amplicons derived from the mutant DNA template, the forward PCR primer was designed with a two base mismatch (Table 1) . After purification of the amplified fragments with a MinElute PCR Purification Kit (QIAGEN, Chatsworth, CA, USA), PCR products were digested with 5U of XbaI (TaKaRa) for 1-2 hours, and electrophoresed in either a 10% acrylamide gel or a 2% NuSieve/1% agarose gel, followed by ethidium bromide staining as described in our previous report [19] . The gels were photographed using an ultraviolet light transilluminator. Table 1 . Primer sequences and annealing temperature used for amplification of the fragments of human ARAF, BRAF, CRAF, K-RAS, N-RAS and MET genes from genomic DNA, and ARAF, BRAF, CRAF, MET and PBGD* 1) genes from cDNA 
ARAF, CRAF, RAS and MET gene analysis
PCR primers and conditions as listed in Table 1 were used to amplify the selected exons of ARAF, CRAF, RAS and MET genes. The amplified products were purified by MinElute PCR Purification Kit (Qiagen) and sequenced on an ABI PRISM 3100 automated capillary DNA Sequencer using the BigDye terminator Cycle Sequencing Ready Reaction Kit v.3.0 (Applied Biosystems, Foster City, CA, USA).
RNA extraction from cells and RT-PCR analysis
RNA was extracted from cells with ISOGEN (NIPPON GENE, Tokyo, Japan) according to the recommendations of the manufacturer. We extracted RNA from human thyroid carcinoma cell lines ARO, FRO, KTC-3, TPC-1, NPA, WRO and primary thyrocyte cultures. ARO, NPA and WRO were kindly provided by Dr. J. A. Fagin (University of Cincinnati College of Medicine). Another papillary thyroid cancer cell line TPC-1, and an anaplastic carcinoma cell line KTC-3 were kindly provided by Dr. Sato (Cancer Institute, Kanazawa University, Japan) and Dr. Kurebayashi (Kawasaki Medical School, Kurashiki, Japan), respectively. Primary human thyroid cell culture was established as described previously [20] . Informed consent was obtained from thyroidectomized patients. Extracted RNA was treated with Deoxyribonuclease I, Amplification Grade (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's protocol. One microgram of RNA was used for cDNA synthesis performed with Superscript TM II Reverse Transcriptase (Invitrogen) and random primers (Invitrogen). The samples were stored at -80°C until used. Each cDNA sample was subjected to PCR to confirm the expression of ARAF, BRAF, CRAF, MET and PBGD as a housekeeping gene using corresponding primers (Table 1) . After amplification, PCR products were separated in a 1.5% agarose gel, stained with ethidium bromide and visualized in UV light.
Results
ARAF, BRAF, CRAF and MET expression in human thyroid cancer cell lines and primary thyrocyte cultures
To examine whether the genes of interest are expressed in human thyroid carcinoma cells and primary cultured thyrocytes, ARAF, BRAF, CRAF and MET mRNA presence were examined by RT-PCR. In all types of cells tested, expression of the genes was confirmed although at differing levels (Fig. 1) .
Mutation analysis of MET, RAS, ARAF, BRAF and CRAF genes
We first performed PCR-RFLP analysis of BRAF T1799A mutation, using a rapid and accurate detection method [19] , in 129 genomic DNA samples from PTC paraffin blocks. BRAF T1799A was detected in 65 (50.4%) of 129 cases. Next, to examine the involvement of other RAF family genes, we analyzed ARAF and CRAF regions corresponding to exons 11 and 15 of BRAF gene. As a result, no mutations of kinase regions of ARAF and CRAF were found in BRAF T1799A negative samples ( Table 2) . Analysis of MET, K-and N-RAS genes also showed the intact sequence patterns in all BRAF T1799A negative samples tested.
Discussion
Our study of the fragments of genes encoding RAF family kinases demonstrated that, in contrast to a high frequency rate of BRAF T1799A , ARAF and CRAF mutations are absent in PTC. Perhaps this finding is induced by distinct biological properties of each proteins RAF protein family despite the high conservation of their primary sequence, especially that of the kinase domain. Several studies have shown that tissue distri- bution and the ability to phosphorylate downstream molecules differ between RAF isoforms [21] [22] [23] .
CRAF is expressed ubiquitously. ARAF is expressed in most murine tissues, but its levels vary widely being high in urogenital tissues (epididymis, seminal vesicle, kidney, testis and ovary) and low in neuronal tissue and skeletal muscle [24] [25] [26] . BRAF is expressed in a tissue-specific manner with higher levels in hemopoietic cells, neurons, and testicular tissue [27] . Our study demonstrated the expression of not only BRAF and CRAF but also of ARAF in primary cultured thyrocytes and thyroid carcinoma cell lines. Although all RAF isoforms can activate MEK, the activity of each protein is differentially regulated by upstream stimuli or other interacting molecules [28] . ARAF and CRAF are activated more effectively by the oncogenic tyrosine kinase Src than by RAS, and both of these synergize to yield the maximal activation [29] . On the other hand, BRAF can be activated by oncogenic RAS alone. ARAF binds to RAS more weakly and is also a feeble MEK activator compared to BRAF and CRAF. Thus, BRAF displays a higher affinity for MEK-1 and MEK-2 than CRAF [30, 31] , resulting in their more efficient phosphorylation [29, [32] [33] [34] [35] [36] . Besides the signal from RAS, RAF activity is regulated through phosphorylation/dephsophorylation and protein-protein interactions with other signaling pathways [28] . For example, RET/PTC-induced MAPK activation in thyroid cells is mediated by BRAF [37] . Taken together, BRAF is likely to possess a stronger transforming activity than ARAF and CRAF once an oncogenic mutation occurs.
In line with our results, Fransen et al. found one germline exonic and nine germline intronic genetic variants of ARAF and CRAF but no somatic mutations in 130 primary colorectal carcinomas [38] . Another ARAF study showed that only MOLT-4 leukemia cell line harbored mutant gene among 60 human cancer cell lines and 323 primary cancer tissues including colorectal carcinomas, gastric carcinomas, ovarian tumors and acute leukemia [39] .
One more gene examined in this work was MET. Overexpression of MET protein has been generally accepted as a distinctive feature of PTC irrespective of histological variants [40] . The protein overexpression was not associated with amplification or rearrangements of MET gene, and MET protein produced by tumor cells did not show major structural alterations [14] . Point mutation of MET gene was identified in papillary carcinoma of the kidney [41] . It is worth noting that MET gene overexpression occurs in PTC in parallel or as a consequence of other oncogenic alterations such as RET/PTC or TRK rearrangements [14] and therefore it comprises a rather late event in PTC development. As MET accumulation, taking place either due to the enhanced transcription of MET gene or posttranscriptional mechanisms, leads to the activation of MAPK signaling, we suggested that point mutations of MET gene might underlie its overexpression in a subset of PTCs without BRAF or RAS mutations. Eventually, this assumption found no experimental proofs in this work as in all cases studied MET sequence appeared to be intact.
As a whole, our investigation demonstrates that unlike BRAF, mutations of other genes encoding RAF family kinases, ARAF and CRAF, and also HGF/SF receptor, MET, do not play an important role in the molecular pathogenesis of PTC. It seems possible that in PTC cases without classical mutations there may be mutation(s) or epigenetic alteration(s) of other gene(s) contributing to MAPK pathway activation, a continuous stimulation of MAPK signaling by an upstream factor/receptor (e.g. MET) and alteration(s) of distinct pathway(s) that provide a proliferative drive to the cells similar to or in combination with the MAPK cascade. 
